---
:selected:
- :type: Secondary
  :text: To assess the effect of xanomeline TTS on the measure of behavioral/neuropsychiatric
    symptoms in participants with  Alzheimer’s Disease
- :type: Secondary
  :text: To document the safety profile of the xanomeline TTS.
- :type: Primary
  :text: To assess the effect of Xanomeline Transdermal Therapeutic System (TTS) on
    the ADAS-Cog and CIBIC+ scores at Week 24 in participants with Mild to Moderate
    Alzheimer’s Disease
- :type: Primary
  :text: To assess the dose-dependent improvement in behavior. Improved scores on
    the Revised Neuropsychiatric Inventory (NPI-X) will indicate improvement in these
    areas
:not_selected:
- :type: Not Set
  :text: To assess the dose-dependent improvements in activities of daily living.
    Improved scores on the [assessment] will indicate improvement in these areas
